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1. Introduction
Protein–protein interactions (PPIs) control many important
physiological processes within human cells.[1] The ability of
specific proteins to interact with high specificity and affinity
has been observed in processes both beneficial and detrimen-
tal to health. Additionally, changes in these interactions can
lead to specific cellular processes malfunctioning, potentially
resulting in biologically undesirable effects, for example the
ability of cancer cells to avoid apoptosis. The modulation of
PPIs has the potential to return physiological processes to
healthy states, and as such there is much interest in the devel-
opment of agents which will allow such control.[2] This task,
however, is not a trivial one, with PPIs historically being consid-
ered “undruggable” because of their large and shallow interfa-
ces.[3] In recent years new approaches have been developed to
effectively target PPIs using both computational and experi-
mental approaches.[3b,4] This has resulted in the preparation of
a number of small-molecule modulators, with more than 12
candidates currently in clinical trials.[5]
Proteins of the Bcl-2 family regulate the intrinsic mitochon-
drial cell death pathway with the family consisting of both
pro- and anti-apoptotic members.[6] Over the past decade
there has been significant interest in the PPIs of the Bcl-2
family due to the role they play in apoptosis (we refer the
reader to reference [7b] for a detailed discussion of the Bcl-2
family proteins).[7] The ability of cancer cells to avoid apoptosis
plays a large role in tumour progression and drug resistance.[7a]
The Bcl-2 family consists of both pro-apoptotic proteins, anti-
apoptotic proteins and regulators. The pro-apoptosis proteins
include BAX and BAK, and are triggered through their interac-
tion with activating regulators BIM, BID, and PUMA.[8] The inter-
action between the pro-apoptotic proteins and regulators is
a key element of cell death. Anti-apoptotic proteins such as
Bcl-2, Bcl-xL and Mcl-1 prevent activation of BAX or BAK by
binding the activating regulators or the pro-apoptosis proteins
themselves, keeping cells alive.[9] This prevents BAX and BAK
from oligomerising and puncturing the outer mitochondrial
membrane resulting in the release of cytochrome C into the
cytoplasm. This is a rapid and irreversible process which acti-
vates downstream caspases and is the point of no return for
the cell. The anti-apoptotic proteins are modulated by sensitis-
er regulators including BAD and NOXA, which do not activate
BAX or BAK, but preferentially bind to Bcl-2, Bcl-xL and Mcl-1,
deactivating them. The overexpression of anti-apoptotic pro-
teins is commonly observed in a number of human cancers, re-
sulting in cell survival.[10] These proteins share regions of ho-
mology named Bcl-2-homology (BH) domains. The regulating
proteins are BH3-only proteins (meaning they only possess ho-
mology in the BH3 region) and are induced through cellular
stress death signals. These proteins bind through hydrophobic
and electrostatic interactions between the BH3 region and the
binding groove formed by the BH1, BH2 and BH3 regions of
the pro- and anti-apoptotic proteins.[11] Candidates are already
in clinical trials which inhibit Bcl-2 and Bcl-xL and have been
shown to induce apoptosis as BH3 mimetics (see reference [12]
for a recent review). However, the inability to inhibit all anti-
apoptotic proteins, in particular Mcl-1, has been shown to
result in drug resistance.[7a] Despite being one of the most fre-
quently amplified genes in cancer and being a major factor in
The ability of protein–protein interactions to regulate cellular
processes in both beneficial and detrimental ways has made
them obvious drug targets. The Bcl-2 family of proteins under-
go a series of protein–protein interactions which regulate the
intrinsic cell-death pathway. The pro-survival members of the
Bcl-2 family, including Bcl-2, Bcl-xL, and Mcl-1, are commonly
overexpressed in a number of human cancers. Effective modu-
lators of members of the Bcl-2 family have been developed
and are undergoing clinical trials, but the efficient modulation
of Mcl-1 is still not represented in the clinic. In addition, Mcl-
1 is a major cause of resistance to radio- and chemotherapies,
including inhibitors that target other Bcl-2 family members.
Subsequently, the inhibition of Mcl-1 has become of significant
interest to the scientific community. This review covers the
progress made to date in modulating the activity of Mcl-1, by
both stapled peptides and small molecules. The development
of peptides as drug candidates, and the advancement of ex-
perimental and computational techniques used to discover
small molecules are also highlighted.
[a] Dr. A. M. Beekman, Dr. L. A. Howell
School of Pharmacy, University of East Anglia
Norwich Research Park, Norwich, Norfolk, NR4 7TJ (UK)
E-mail : L.Howell@uea.ac.uk
 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
This is an open access article under the terms of the Creative Commons At-
tribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
ChemMedChem 0000, 00, 0 – 0  0000 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim1 &
These are not the final page numbers! 
MinireviewsDOI: 10.1002/cmdc.201500497
resistance to chemotherapy, Mcl-1 has proven the most elu-
sive, with no candidates currently in clinical trial. The pro-sur-
vival Bcl-2 family proteins sequester the a-helical BH3 domain
of the pro-death Bcl-2 family, in the binding groove created by
the BH1-3 domains. However, Mcl-1 differs from the other pro-
survival members, possessing a more electropositive binding
groove,[8] with a number of different residues.[13] Additionally,
the Mcl-1 groove has been shown to be more rigid than the
other pro-apoptosis members,[14] making specific modulators
difficult to obtain.
Several examples of small molecules which modulate Mcl-
1 have been reported, with a variety of reviews addressing pa-
tented compounds,[15] compounds in clinical trials[8] and pan-
Bcl-2 inhibitors.[16] Most recently, Belmar and Fesik presented
an excellent review of Mcl-1 binders which are known to be
BH3 mimetics.[17] The scope of this review will target a compre-
hensive overview of known Mcl-1 binders which have been
demonstrated to inhibit the PPIs of Mcl-1 with the
pro-apoptotic and regulating proteins from the Bcl-2
family, complementing the work which has already
been presented before us.
2. Stapled Peptides
In general terms there are two major classes of ap-
proved drugs: small molecules and protein therapeu-
tics.[18] A small-molecule inhibitor of a PPI is generally
much smaller than the protein it is inhibiting, there-
fore limiting the number of interactions it can make.
However, the presence/requirement of a hydrophobic
groove or pocket enables the design of small mole-
cules capable of inhibiting the protein of interest,[19]
and small-molecule inhibitors of Mcl-1 are discussed
in detail below. By contrast, protein therapeutics are
much larger and have a greater surface area in which
to make contact with the target. Therefore, they do
not need such defined binding pockets and can ef-
fectively bind to flatter, shallower surfaces which are
not necessarily hydrophobic. However, this class of drug is
unable to cross the cell membrane, so is therefore limited to
extracellular targets. An alternative and attractive option for
stabilising or disrupting PPIs are peptides.[20] However, in vivo
their efficacy is compromised due to a loss in secondary struc-
ture as well as poor cellular uptake and susceptibility to pro-
teolysis. A promising synthetic approach to overcome these
limitations is to “staple” the peptide to fix its orientation.[21] In
addition to being a potential new class of therapeutics capable
of inhibiting the Bcl-2 proteins, they may also prove useful
chemical biology tools for probing these key proteins and fur-
thering our understanding of the processes governing apopto-
sis.
Peptide stapling was first introduced by Verdine and co-
workers in 2000[22] who then went on to employ the concept
to identify peptide-based inhibitors of Bcl-2 proteins designed
on the structure of the BH3 domain of the BID protein (Table 1,
Figure 1), so called “stabilised a-helix of BCL-2 domains”
(SAHBs).[20] BID SAHBA was able to specifically activate the
apoptosis pathway in leukaemia cells and inhibit the growth of
leukaemia xenografts in vivo. Further characterisation of the
peptide demonstrated it bound to and activated BAX direct-
ly.[23] Following this pioneering work a variety of BH3-only pep-
tide domains were used to synthesise stapled peptides capable
of modulating apoptosis.[24]
In 2010 Loren Walensky’s group identified the first stapled
peptide capable of selectively inhibiting Mcl-1 (Table 1).[25] The
development of such selective inhibitors is a major challenge
due to the very subtle differences between the Bcl-2 family
proteins in terms of their hydrophobic grooves. A series of sta-
pled peptides based on the BH3 domains of both pro- and
anti-apoptotic Bcl-2 proteins were designed and assessed for
their ability to inhibit Mcl-1 by fluorescence polarisation (FP)
assay. Those that bound Mcl-1 with a high affinity were further
evaluated against a panel of anti-apoptotic targets and the
Mcl-1 BH3 helix was found to be a potent and selective inhibi-
tor of Mcl-1 capable of sensitising cells to caspase-dependent
apoptosis. Alanine scanning, site-directed mutagenesis and
staple scanning were used to determine the key binding sites
and specificity determinants as well as the optimal helicity. In-
terestingly, X-ray crystallography and mutagenesis studies re-
vealed the hydrocarbon staple itself is capable of making addi-
tional hydrophobic interactions, which along with the en-
hanced a-helicity may be responsible for the enhanced bind-
Table 1. SAHB peptides reported by Verdine[20] and Walensky.[25]
Compound Sequence[a] Helicity [%][b] Kd [nm]
BID BH3 EDIIRNIARHLAQVGDSNLDRSIW 15.70.3 269[c]
BID SAHBA EDIIRNIARHLA*VGD*NLDRSIW 87.50.3 38.8[c]
BID SAHBA(G!E) EDIIRNIARHLA*VED*NLDRSIW 77.80.6 483[c]
BID SAHBB EDIIRNI*RHL*QVGDSNLDRSIW 85.51.3 n.d.
BID SAHBC EDIIRNIA*HLA*VGDSNLDRSIW 59.76.5 n.d.
BID SAHBD EDIIRNIAR*LAQVGD*NLDRSIW 35.61.8 n.d.
Mcl-1 BH3 KALETLRRVGDGVQRNHETAF 18 24529[d]
Mcl-1 SAHBA KALETLR*VGD*VQRNHETAF 62 4316[d]
Mcl-1 SAHBB KAL*TLR*VGDGVQRNHETAF 100
[e] 184[d]
Mcl-1 SAHBC KALETLRRV*DGV*RNHETAF 81 >1000
[d]
Mcl-1 SAHBD KALETLRRVGDGV*RNH*TAF 91 103[d]
Mcl-1 SAHBE KALETLRRVGDGVQR*HET*F 68 3310[d]
[a] *: Indicates location of hydrocarbon staple. [b] Determined by circular dichroism.
[c] Determined by a Bcl-2 FP assay; 95% CI BID BH3 33.5–44.9 nm, BID SAHBA 244–
297 nm, BID SAHBA(G!E) 434–536 nm. [d] Determined by an Mcl-1 FP assay; data are
the meanSD performed in at least triplicate; n.d. : not determined. [e] Exceeds calcu-
lated ideal value for undecapeptide standard.
Figure 1. Fmoc-protected amino acid building block and the BID SAHBA hy-
drocarbon-stapled peptide.
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ing affinity of Mcl-1 SAHBD. This was later supported by molec-
ular dynamics simulations.[26] The Walensky group then went
on to use these stapled peptides, specifically Mcl-1 SAHBA as
a screening tool to identify small molecules (described
below).[27]
In 2012 Lin and co-workers reported the design of proteolyt-
ically stable and cell permeable peptide-based inhibitors of
Mcl-1 (Table 2).[28] Rather than employing a hydrocarbon cross-
link as used by Verdine and Walensky, a bis-aryl staple was in-
corporated into a Noxa peptide which binds to Mcl-1 with
high affinity and selectivity. Two solvent-exposed i and i+7
residues were replaced with d- or l-cysteine and the peptide
subjected to 4,4’-bis(bromomethyl)biphenyl (Bph)-mediated
cross-linking.[29] The resulting cross-linked peptides possessed
enhanced inhibitory activity when compared to the parent
Noxa peptide whilst still maintaining selectivity. However, the
compounds were inactive in cellular assays due to poor
uptake. Replacement of three solvent exposed, positively
charged residues (Arg6, Arg14, and Lys16) improved affinity
(roughly twofold increase) but more importantly led to in-
creased cellular activity. N-Methylation of both N-terminal ala-
nine residues led to improved activity in both the FP assay as
well as in the cell viability assay. Fluorescence-activated cell
sorting (FACS) analysis of fluorescently tagged versions of the
peptides confirmed increased cellular uptake and confocal mi-
croscopy showed the peptides were predominantly localised
in the cytosol. Finally the stapled peptides were shown to pos-
sess enhanced stability toward proteases.
In 2014, Lin went on to report the effects of the flexibility/ri-
gidity as well as the length of the cross-linker;[30] suggesting
a more flexible cross-linker may allow the peptide to adopt
a more favourable/active conformation when bound to its pro-
tein partner. A series of aryl and vinylaryl cross-linkers with
varying linker length, rigidity and hydrophobicity were syn-
thesised (again using the Noxa BH3 peptide) and the com-
pounds evaluated for inhibitory Mcl-1 activity using a competi-
tive FP assay. Analogues containing a 6,6’-bis(bromomethyl)-
3,3’-bipyridine (Bpy) or p-phenylene-3,3’-bis(allylbromide)
cross-linker appeared to have the highest helicity which trans-
lated into the highest inhibitory activity in the FP assay, where-
as cellular uptake correlated with hydrophobicity with the ana-
logues containing the Bph staple or a 3,3’-bis(bromomethyl)bi-
phenyl variant showing the most efficient cellular uptake.
Taken together these results suggest the stapling of pep-
tides is a promising new approach to targeting PPIs, specifical-
ly Mcl-1 and other Bcl-2 family proteins. The bioactive confor-
mation of the peptide is maintained whilst overcoming the
drawbacks of using peptides as drug molecules; careful posi-
tioning and choice of staple can result in a high-affinity binder
with improved cellular uptake and stability.
3. Small-Molecule Inhibitors
3.1 Antimycin A
In 2001 Tzung and co-workers reported that antimycin A, a nat-
ural product antibiotic isolated from a Streptomyces sp. , mark-
edly increased the apoptosis induced cell death in cell lines
possessing Bcl-xL associated multidrug resistance.
[31] Through
docking studies, they showed that the binding groove of the
Bcl-2 family proteins was occupied by antimycin, confirmed by
their fluorescence assays on Bcl-2 and Bcl-xL. Reed and co-
workers subsequently demonstrated the ability of antimycin A
to competitively bind to Mcl-1 at similar concentrations to Bcl-
2 and Bcl-xL (IC50=2.51 mm, FITC-Bid BH3-only peptide).
[32]
3.2 BH3I-1
Yuan and co-workers highlighted three compounds from
a competitive FP binding assay of the Bcl-xL-BH3 site and Bak.
These three compounds, titled BH3I-1 (BH3 Inhibitor-1), BH3I-1’
and BH3I-2, induced apoptosis in JK cells, showing the charac-
teristic features of over-expression of pro-apoptotic Bcl-2
family proteins.[33] Yuan showed that BH3I-1 acts by preventing
the heterodimerisation of the pro-apoptotic and anti-apoptotic
Bcl-2 proteins, and identified the binding site through NMR
studies. Reed demonstrated that BH3I-1 is a competitive Mcl-
1 binder with an IC50 of 2.17 mm (FITC-Bid BH3-only peptide).
[32]
3.3 BH3M6
In 2002 Hamilton and co-workers synthesised a number of
compounds which were designed to mimic the binding resi-
dues of the Bcl-2 family proteins.[34] Using the crystal structure
of Bak/Bcl-2 they identified a number of hydrophobic residues
Table 2. Stapled Noxa peptides described by Lin and co-workers.[28]
Compound Sequence[a] Ki [nm]
[b] Cell Viability [%][b]
Noxa AAQLRRIGDKVNLRQKLLN 648128 97.60.9
Noxa 1 AAC’LRRIGDC’VNLRQKLLN 101 98.64.0
Noxa 2 AAc’LRRIGDC’VNLRQKLLN 5414 100.30.2
Noxa 3 AAc’LRAIGDC’VNLRQKLLN 238 85.92.2
Noxa 4 AAc’LRAIGDC’VNLAQKLLN 2811 72.93.2
Noxa 5 AAc’LRAIGDC’VNLAQALLN 294 44.30.2
Noxa 6 AmAc’LRRIGDC’VNLRQKLLN 323 87.32.8
Noxa 7 AmAmc’LRRIGDC’VNLRQKLLN 224 80.54.7
Noxa 8 AmAmc’LRAIGDC’VNLAQALLN 228 34.80.5
[a] C’=Bph-linked l-Cys, c’=Bph-linked d-Cys, Am=N-methylalanine.
[b] Data are the meanSD, n=3.
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which were shown to participate in binding by alanine scan-
ning. This structure guided design resulted in the preparation
of BH3M6. Hamilton demonstrated that BH3M6 was able to in-
hibit the binding of Bak and Bcl-xL with a Kd=1.89 mm. In 2011
Sebti and co-workers demonstrated that BH3M6 inhibits the
binding of Mcl-1 to Bax and Bim in a dose-dependent manner
in HEK293T and A549 cells.[35] Sebti also demonstrated that
BH3M6 can induce apoptosis by acting as a pan-inhibitor and
disrupting the formation of Bcl-xL/Bim, Bcl-2/Bim and Mcl-1/
Bim heterodimers.
3.4 YC137
In 2001 Wang and Yang performed a virtual screen of 206876
compounds based on an NMR structure of Bcl-2, and then per-
formed a subsequent in vitro assay which highlighted 35 of
these structures.[36] In 2004 Wang proceeded to report the ex-
ploration and elaboration of these structures, which highlight-
ed YC137 as a potent Bcl-2 inhibitor.[37] Reed again showed
this compound to be a strong Mcl-1 binder, demonstrating an
IC50 of 2.47 mm in their FP assay (FITC-Bid BH3-only peptide).
[32]
Despite the competitive binding ability, and the recognised se-
lectivity of YC137 for Bcl-2 family members, the structure has
received little attention in the literature regarding the activity
toward Mcl-1.
3.5 EGCG
There has been much attention in the literature regarding the
anticancer ability of compounds found commonly in green
and black tea.[38] In 2003 Pellecchia and co-workers reported
the examination of a number of natural compounds found in
significant quantities in green and black tea, with a particular
interest in their ability to bind the Bcl-2 family. They showed
that ()-epigallocatechin gallate (EGCG) had binding affinities
in the nanomolar range for Bcl-2 (Ki=490 nm) and Bcl-xL (Ki=
335 nm, FITC-BAD-BH3-only peptide competitive binding
assay).[39] Computational docking studies revealed that EGCG
bound to the BH3 domain. Reed and co-workers demonstrated
that EGCG was a pan-inhibitor of the Bcl-2 family.[32] Recently,
it has been shown that in several cancer cell lines (786-O renal
cell carcinoma, HNSCC, Pc-3 and LNCaP), EGCG binds upstream
of the Bcl-2 family, resulting in downregulation of the anti-
apoptosis proteins.[40]
3.6 ()-Gossypol (AT-101)
In 2002 Wang and co-workers patented the use of ()-gossy-
pol (AT-101) as a Bcl-2 family antagonist, after performing
a structure-based database screen.[41] Gossypol was shown to
bind to Bcl-xL and Bcl-2 with high affinity (320 nm and 480 nm
respectively),[42] as well as to Mcl-1 (180 nm, FITC-Bad-BH3-only
peptide). Subsequently, gossypol was advanced to clinical trials
as a small-molecule inhibitor of Bcl-xL, Bcl-2 and Mcl-1.
[43] In
2004 Bradford and co-workers reported that ()-gossypol was
acting as a BH3 domain mimetic, making it a pan inhibitor of
the Bcl-2 family of proteins.[44] Subsequently, ()-gossypol was
shown to delay the onset of androgen-independent prostate
cancer in vivo,[45] chemosensitise prostate cancer cells (PC-3) to
docetaxel both in vitro and in vivo, and was proven to increase
the availability of the pro-apoptotic proteins Puma and
Noxa.[46]
3.7 TW-37
In 2006 Wang et al. reported the structure-based design of
a new series of Bcl-2 family binders, based on the exploration
of the structure activity relationship of gossypol.[47] The Bcl-2
protein was targeted, with computational docking calculations,
to examine which functional groups played the largest role in
gossypol’s affinity to Bcl-2. It was shown that the polyphenol
system was of high importance, and the hydrophobic section
of the molecule could be extended to better fit into the bind-
ing pocket. After a series of iterations Wang and co-workers
prepared TW-37, which showed a high affinity for Bcl-2 (Ki=
290 nm) and Mcl-1 (Ki=260 nm), but lower affinity for Bcl-xL
(Ki=1110 nm, FAM-Bid-BH3-only peptide competitive binding
assay). Wang and co-workers went on to show that TW-37 in-
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hibits cell growth in the prostate cancer cell line PC-3 with an
IC50 value of 200 nm, and induces apoptosis in 89.5% of cells
at 5 mm.[47]
In 2007 Mohammad and co-workers demonstrated that TW-
37 resulted in the inhibition of cell proliferation of lymphoma
cells (WSU-DLCL2 290 nm) and induced apoptosis in 71.4% of
cells at 400 nm.[48] Furthermore, they showed that TW-37 en-
hances the efficacy of the four drug combination cyclophos-
phamide-doxorubicin-vincristine-prednisolone (CHOP) in mice
models, displaying significant decrease in tumour weight rela-
tive to CHOP alone, TW-37 alone or the control.[48] These re-
sults were similarly reflected in the examination of B-cell
tumour cell lines by Katib and co-workers.[49]
3.8 Apogossypolone (ApoG2)
Apogossypolone (ApoG2) is a gossypol derivative prepared by
Mohammad and co-workers in 2008.[50] It was shown to pos-
sess low nanomolar affinity for Bcl-2 (Ki=35 nm) and Mcl-1
(Ki=25 nm, competitor not published). Examination of the ac-
tivity of apogossypolone in Follicular Lymphoma cells (WSU-
FSCCL) showed an IC50 of 109 nm, and decreased cell numbers
in a fresh lymphoma sample. Apogossypolone was demon-
strated to prompt apoptosis, with an activation of the apopto-
sis inducing factor, suggesting that apogossypolone was
acting as a BH3 mimetic.
3.9 Obatoclax
Obatoclax was developed by Gemin X,[15] a developmental pro-
gram focussed on modulating the anti-apoptototic proteins of
the Bcl-2 family.[51] It was demonstrated to be a pan-Bcl-2 in-
hibitor by Reed and co-workers,[32] but was shown by Shore to
be more potent than the original FP assay suggested, due to
the low solubility in aqueous medium.[51] Shore went on to dis-
play that obatoclax overcomes resistance to apoptosis confer-
red by Mcl-1, restoring sensitivity to the known Bcl-2 antago-
nist ABT-737, by increasing the presence of Bim in the cell. Ad-
ditionally, obatoclax displayed single-agent antitumour activity
in multiple standard mouse tumour models.[51] Obatoclax was
shown to bind tightly to Mcl-1 by inducing a histidine (His252)
side chain hydrogen bond, in a narrow groove of the binding
site, which is conserved in several Bcl-2 family members.[52] Ob-
atoclax was also found to increase the activity of cisplatin in
both resistant and sensitive cell lines, overcoming platinum re-
sistance in the former and restoring mitochondrial apoptosis.[53]
Obatoclax has been investigated in several phase I/II clinical
trials, both as a single agent and in combination. However to
date, the data available suggests a low therapeutic activity of
obatoclax.[12]
3.10 S1
Zhang and Qian reported in 2007 the design of compounds
termed S1 and S2, and demonstrated them to be cytotoxic
compounds.[54] Flow cytometry showed that S1 was inducing
apoptosis in vitro, and subsequent analysis showed that this
was also the case in vivo. Examining the process upstream,
Zhang showed that S1 bound to Bcl-2, via NMR-based binding
assays, and demonstrated through computational docking that
S1 and S2 were binding in the BH3 domain. S2 was shown to
have an IC50 of 1.3 mm to HL-60 cells and S1 to have an IC50 of
2.8 mm, reproducing their computational predictions.[54a] Zhang
reported in 2011 that S1 was also an Mcl-1 inhibitor, prevent-
ing the Mcl-1/Bak dimerisation, claiming it to be the first re-
ported “authentic BH3 mimetic”.[55] In 2013 Zhang demonstrat-
ed that S1 shows activity toward a variety of leukaemia cell
lines, including acute lymphoblastic leukaemia, acute myeloid
leukaemia, chronic lymphoblastic leukaemia and chronic mye-
loid leukaemia.[56] While S1 inhibited Mcl-1 and Bcl-2 as expect-
ed, the protein Bcl-2 did provide resistance to S1, and the ratio
of these proteins allowed for the prediction of the cytotoxicity
of S1. Elaboration of S1 and S2 led to product 1, which
showed a 9- to 35-fold higher affinity for Mcl-1, Bcl-2 and Bcl-
xL than S1, displaying IC50 values of 10, 20, and 18 nm, respec-
tively (ELISA).[57]
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3.11 Meiogynin A derivatives
In 2009 Gueritte and co-workers isolated meiogynin A from the
bark of Meiogyne cylindrocarpa, a Malaysian plant, and demon-
strated it to be a Bcl-xL inhibitor.
[58] Subsequently, in 2014
Roussi and co-workers reported the preparation of a number
of meiogynin A derivatives, designed by a structure activity re-
lationship study, which was reported at the time to be “one of
the most potent dual inhibitors” of Mcl-1 and Bcl-xL.
[59] The
most effective compound, titled Roussi compound 2a, pos-
sessed Ki values of 106 nm for Mcl-1 (Bid-BH3 only FP assay)
and 153 nm for Bcl-xL (Bak-BH3 only FP assay). In addition, the
selective Mcl-1 inhibitor Roussi compound 2c showed Ki values
of 460 nm for Mcl-1 (Bid-BH3 only FP assay) and >23 mm for
Bcl-xL (Bak-BH3 only FP assay).
3.12 Sabutoclax
In 2009 Pellecchia and co-workers examined the derivatisation
of gossypol guided by NMR binding assays and computational
docking.[60] From the library of compounds Pellecchia prepared,
racemic BI97C1 (originally compound 8r) was the most effec-
tive, demonstrating IC50 values of 0.28 mm for Mcl-1 and
0.32 mm for Bcl-2 (FITC-Bak-BH3-only peptide), as well as bind-
ing to Bcl-xL and Bfl-1. Additionally, Bl97C1 was shown to
induce apoptosis in the RS11846 human lymphoma cell line. In
a follow up publication, Pellecchia et al. examined the stereo-
chemistry of Bl97C1, demonstrating that the (R,-,R) enantiomer
(displayed) inhibits the binding of BH3 peptides to Bcl-xL, Bcl-2,
Mcl-1, and Bfl-1 with IC50 values of 0.31, 0.32, 0.20, and 0.62 mm
(FITC-Bak-BH3-only peptide).[61] Additionally, inhibition of the
cell growth of human prostate cancer, lung cancer, and BP3 B-
cell lymphoma cell lines with EC50 values of 0.13, 0.56, and
0.049 mm, respectively was demonstrated.
Following this Pellecchia and co-workers examined the elab-
oration of apogossypolone in a similar manner as gossypol.[62]
The study highlighted racemic BI97D6 as a potential candidate,
demonstrating inhibition of Bcl-xL, Bcl-2, Bfl-1, Mcl-1 at IC50
values of 0.34 mm, 0.29 mm, 0.65 mm, and 0.24 mm, respectively
(FITC-Bak-BH3-only peptide). Pellecchia again followed this
with an examination of the stereochemistry, highlighting ()-
BI97D6 (displayed) as a potent binder. ()-BI97D6 demonstrat-
ed binding inhibition of Bcl-xL, Bcl-2, Mcl-1, and Bfl-1 with IC50
values of 76, 31, 25, and 122 nm, respectively in FP assays
(FITC-Bak-BH3-only peptide).[63] Additionally, ()-BI97D6 inhibit-
ed growth of the PC-3 human prostate cancer and H23 human
lung cancer cell lines with EC50 values of 0.22 and 0.14 mm, re-
spectively. Subsequently, Andreeff and co-workers demonstrat-
ed that ()-BI97D6 overcomes ABT-737 resistance in acute
myeloid leukaemia.[64]
3.13 Marinopyrrole A derivatives
Marinopyrrole A is a natural product antibiotic isolated from
a Streptomyces sp. reported in 2009.[65] It was described by
Wang and co-workers to possess the ability to overcome ABT-
737 resistance by inhibiting the action of Mcl-1.[66] However, it
was subsequently reported to have no effect on Mcl-1 in cells,
and exhibits the same action on Bcl-2-dependent cells (2 mm)
as Mcl-1-dependent cells (2.5 mm).[67] In 2015 Qin and co-work-
ers reported the preparation of a number of analogues of mar-
inopyrrole A, following a structure activity relationship study.[68]
The talismanic compounds of this study were titled Qin com-
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pound 34, which showed 16 fold selectivity for Mcl-1 (IC50=
6.1 mm, Bim-BH3-only peptide, ELISA) compared with Bcl-xL
(IC50> 100 mm, Bim-BH3-only peptide, ELISA), and Qin com-
pound 42, which showed potent activity for both Mcl-1 and
Bcl-xL (IC50=0.6 mm, 0.5 mm respectively, Bim-BH3-only peptide,
ELISA). However despite being highly potent in the ELISA,
compound 42 had little activity in intact breast cancer cells.
3.14 Chai compounds 6 & 7
In 2010 Chai and co-workers addressed the problem of identi-
fying a selective Mcl-1 inhibitor.[69] All Mcl-1 inhibitors previous-
ly reported had been pan-Bcl-2 inhibitors, with moderate to
weak activity, making overcoming Mcl-1 induced resistance
a challenge. Chai screened a library of compounds which in-
corporated known Bcl-2 family binders BH3I-1 and sanguinar-
ine with a FP assay using Mcl-1 and Bak.[70] This screening high-
lighted two compounds, referred to in the original literature as
compounds 6 and 7. These constitutional isomers showed sig-
nificant differences in selectivity, with Chai compound 6 dis-
playing binding in the micromolar range to both Bcl-xL (Ki=
3.7 mm) and Mcl-1 (Ki=6.9 mm), and Chai compound 7 showing
selectivity toward Mcl-1 (Ki=8 mm) with no binding to Bcl-xL
(Ki> 100 mm, Flu-Bak-BH3 peptide competitive binding).
[69]
Both compounds showed greater binding in their assays than
BH3I-1, with NMR studies demonstrating that the compounds
were binding in the BH3 domain. Docking studies demonstrat-
ed that the Mcl-1 binding groove is wider than that of Bcl-xL,
which may explain the selectivity being displayed by the two
constitutional isomers.[69]
3.15 MIM1
In 2010 Walensky and co-workers
showed that the BH3 domain of
Mcl-1 was a potent and selective
natural inhibitor of Mcl-1.[25] This
prompted the use of the fluores-
cently tagged BH3 domain of Mcl-
1 as the competitive binding agent
for their FP assays, allowing for
a selective and potent Mcl-1
binder to be identified. 71296 compounds were screened for
the ability to displace a FITC tagged Mcl-1 BH3 domain pep-
tide, and stringent selection processes highlighted MIM1 as
a potent and selective Mcl-1 binder.[27] MIM1 displaced the
FITC-Mcl-1-BH3 peptide at an IC50 of 4.7 mm, but had no signifi-
cant ability to displace Bid from Bcl-2, complementing the ac-
tivity of ABT-737. The ability of MIM1 to induce apoptosis in
Mcl-1-dependent leukaemia cells was also demonstrated.
3.16 Cardone compound 9
Researchers at Eutropics Pharmaceuticals performed a high
throughput screen of 315000 compounds, searching for tar-
gets which inhibit Mcl-1, but do not bind to Bcl-xL. This screen
highlighted a 7-hydroxyquinoline 2, displaying inhibition of
Mcl-1 with an IC50=2.4 mm, with no inhibition of Bcl-
xL(competitive FP assay with FITC-Bim BH3-only peptide).
[71]
Structure activity relationship studies of this compound result-
ed in the preparation of compound 9 which displayed im-
proved affinity for Mcl-1 (IC50=0.31 mm) with relatively low in-
hibition of Bcl-xL (IC50>40 mm) (FITC-Bim BH3-only peptide).
Cardone compound 9 also showed moderately high liver mi-
crosome stability, with a half-life of 55 min in human micro-
somes, and computational studies demonstrated that it was
a BH3 domain binder. Cardone and co-workers showed that
Cardone compound 9 had high activity in a panel of human
derived cancer cell lines, in particular Mcl1-1780 (EC50=
0.3 mm), Bcl2-1863 (EC50=1.1 mm), NCI-H929 (EC50=1.6 mm) and
SUDHL-6 (EC50=3.3 mm). This cytotoxicity was shown to be
a result of apoptosis via Annexin V staining, demonstrating
a complementary activity to ABT-263 in regards to cell lines ex-
pressing high amounts of Bcl-2/Bcl-xL and Mcl-1.
[71]
3.17 Tanaka compound 11
In an attempt to overcome the ability of Mcl-1 to induce resist-
ance to the compounds which target Bcl-2 and Bcl-xL undergo-
ing clinical trials, Tanaka and co-workers envisaged a chimeric
compound which used elements from known Mcl-1 binders
and Bcl-xL binders.
[72] In this manner they used ABT-263 (which
was in clinical trials at the time)[73] and the known Mcl-1 binder
3, to develop a potent inhibitor of both Mcl-1 and Bcl-xL, origi-
nally termed compound 11. Tanaka’s compound 11 demon-
strated IC50 values of 88 nm for Mcl-1 and 3.7 nm for Bcl-xL
(Bid-BH3 only, time-resolved fluorescence resonance energy
transfer assay).
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3.18 Fesik fragment-based screening
In 2013 Fesik and co-workers described the use of a now com-
monly employed technique to target protein–protein interac-
tions. They screened small fragments for micromolar binding,
and then using NMR studies identified the binding sites of
each fragment. With this information in hand each fragment
can be linked together to create a small molecule which pos-
sesses greater binding affinity. In this way the relatively large
protein–protein binding site can be explored rapidly to identify
the important binding motifs.[74] Employing this method, Fesik
was able to identify two important regions, which were bound
to by distinct small molecules, exemplified by 4 (Ki=131 mm)
and 5 (Ki=60 mm, FITC-Mcl-1-BH3-only peptide). Merging these
two fragments generated 6 (Ki=0.32 mm, FITC-Mcl-1-BH3-only
peptide), which was confirmed by crystallography to occupy
both of the pockets identified by the initial fragments. Subse-
quently this molecule underwent structure-guided synthetic
design, which yielded several high-affinity leads, exemplified
by 7 which showed a Ki=0.055 mm, with 10-fold selectivity for
Mcl-1 over Bcl-2 and Bcl-xL (FITC-Mcl-1-BH3-only peptide). Fesik
also described several other potential leads with the same skel-
eton.[74]
3.19 Benzylpiperazine derivatives
In 2013 Liu, Wang, and colleagues reported the use of an inno-
vative computational modelling approach to develop four mo-
lecular scaffolds for synthetic evaluation.[75] Liu and Wang
apply the assumption that critical binding residues of the PPI
exist in small clusters, which can be exploited by small frag-
ments. Using computational docking, one can examine these
small clusters to identify the most appropriate fragments, and
then combine these virtually, with the appropriate chemical
spacing to create molecular scaffolds. In this manner Liu and
Wang developed four backbones, termed series A-D, exempli-
fied by the best performers in each series, A1, B3, C10 and
D14. The A and D series were found to outperform series B
and C in their FP binding assay, with A1 demonstrating a Ki=
0.18 mm and D14 showing a Ki=0.32 mm (Mcl-1/5-FAM-Bid
BH3-only peptide competitive binding assay). These com-
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pounds also showed some selectivity for Mcl-1, with A1 show-
ing no appreciable binding to Bcl-2 or Bcl-xL (5-FAM-Bid BH3-
only peptide).[75]
3.20 UMI-77
In 2014 Nicolovska-Coleska performed a high-throughput
screen to identify small-molecule inhibitors of Mcl-1.[76] They
identified compound 8 which led to the development of UMI-
77 through structure-based chemical modifications. With FP-
based screens Nicolovska-Coleska showed that UMI-77 displa-
ces Bid-BH3 from Mcl-1 with a Ki=0.49 mm, with a 10-fold se-
lectivity, with Bcl-w, Bcl-2, and Bcl-xL displaying Ki>5 mm (5-
FAM-Bid BH3-only peptide). It was also demonstrated that
UMI-77 selectively binds to Mcl-1 in preference to Noxa in
a dose-dependent manner, by binding to the BH3-binding
pocket of Mcl-1. In cell lines, UMI-77 was shown to inhibit the
growth of pancreatic cancer cells (MiaPaCa-2 and AsPC-1) and
showed single-agent antitumour activity toward BxPC-3 cells.
Morgan and co-workers then demonstrated that UMI-77 radio-
sensitised cancer cell lines BxPC-3 and Panc-1, but did not
radio-sensitise normal small intestinal cells.[77] Morgan demon-
strated that ABT-737, which does not bind to Mcl-1, did not
perform in the same manner, suggesting Mcl-1 plays a key role
in radio-sensitising cancer cells.
3.21 A-1210477
Souers and co-workers recently identified 9 through a high-
throughput screen aimed at identifying small-molecule inhibi-
tors of Mcl-1 using the selective protein Noxa.[78] 9 showed mi-
cromolar affinity for Mcl-1 (Ki=4.4 mm), as well as selectivity
over Bcl-xL (Ki>10 mm), in an FP assay. Structure guided
design, incorporating hits which they had generated in previ-
ous reports,[79] allowed for the preparation of A-1210477,
which showed a 10000-fold improvement in affinity for Mcl-1
(Ki=0.43 nm, Noxa BH3-only peptide) compared to 9. A-
1210477 also showed similar selectivity for Mcl-1 with Ki>
0.66 mm for Bcl-2, Bcl-xL, Bcl-w and A1. Activity was proven to
be through the disruption of the Mcl-1 Bim complex in live
cells. A-1210477 was found to induce apoptosis in the cancer
cell line H929 and restore navitoclax sensitivity in the resistant
pancreatic cell line BxPC-3.[80] Similarly in the breast cancer cell
line SKBR3 sensitivity to navitoclax was restored with the addi-
tion of A-1210477 resulting in the release of BAK, demonstrat-
ing the role of Mcl-1 in navitoclax resistance.[81] The molecule is
believed to bind to Mcl-1 in a similar manner to analogue 10
reported in the same manuscript (where the sulfonamide on
the piperazine was replaced with an acetyl group) ; specifically
binding in the BH3 binding domain and mimicking the BIM
BH3 peptide. The central indole binds in the p2 pocket, with
the carboxylate group forming a hydrogen bonding interaction
with Arg263. The naphthyl group was projected toward the p1
pocket and the extended piperazine spanned the p3/p4 pock-
ets. A-1210477 represents the most potent small-molecule in-
hibitor described in the literature to date, and induces clear
on-target cellular activity.
3.22 Pyridoclax
In 2015 Voisin-Chiret and Poulain employed a strategy similar
to that which lead to the discovery of BH3M6.[82] Examining
the binding pocket of Mcl-1, and its differences from the other
Bcl-2 family members, led them to employ an oligopyridine
backbone to act as a BH3-mimetic. Computational modelling
and SAR studies resulted in the preparation of pyridoclax,
which was designed based on the binding of the selective
Mcl-1 binding protein Noxa. Using bioluminescence resonance
energy transfer (BRET) it was shown that pyridoclax binds to
ChemMedChem 0000, 00, 0 – 0 www.chemmedchem.org  0000 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim9 &
These are not the final page numbers! 
Minireviews
Mcl-1 in the cell (Bim/Mcl-1), with a maximum effect observed
at 25 mm. Subsequently it was demonstrated that pyridoclax
sensitises various cancer cells (IGROV1, OAW42-R, SLOV3, A549
and MSTO-211H) to Bcl-xL knock-down, and chemoresistant
ovarian cancer cells to ABT-737 (IGROV1-R10 and SKOV3) at
25 mm, suggesting Mcl-1 selectivity.
4. Summary and Outlook
The discovery of chemical entities capable of modulating PPIs
is a challenging prospect and PPIs have historically been de-
scribed as “undruggable”. However, the efforts of many re-
search groups over the past two decades has defied this view
point with a number of inhibitors progressing through clinical
trials which target the Bcl-2 family (ABT-737, navitoclax and
ABT-199).[73,83] However, despite the recent success in targeting
Bcl-2 and Bcl-xL, the modulation of Mcl-1 with inhibitors has
proven elusive and there are currently no Mcl-1 inhibitors in
clinical trial despite the fact that Mcl-1 is one of the most com-
monly amplified genes in cancer.[84]
Perhaps more promisingly, recent years have seen an in-
crease in interest in targeting Mcl-1 and identifying new inhibi-
tors—both small-molecule and peptide based. Specifically, sta-
pled peptides are a promising new approach to developing
moieties capable of inhibiting PPIs and the examples described
above by Walensky[20] and Lin[28] demonstrate the potential of
this class of therapeutic. Through fixing the conformation of
the a-helix, the active conformation of the peptide is main-
tained leading to an increase in affinity for the protein. In addi-
tion, stapling the peptide can shield the amide bonds of the
peptides protecting them from proteases and also decrease
their ionic character, resulting in an improvement in cellular
uptake (through passive diffusion) and reduced clearance from
the body. With the number of publications reporting stapled
peptides accelerating (just one in 2000 vs 16 in 2013) and the
first clinical trial successfully completed in 2013, the clinical po-
tential of stapled peptides is currently being explored but it re-
mains to be seen if this will translate into the clinic and if sta-
pled peptides are able to fulfil this potential.
The number of publications describing small-molecule inhib-
itors of Mcl-1 has increased rapidly in recent years. However,
a large proportion of the small molecules described have been
identified through high throughput screening of larger libra-
ries, resulting in large attrition rates. In addition achieving se-
lectivity has proved problematic due to the very subtle differ-
ences in binding pockets between the Bcl-2 family; the p2
pocket of Mcl-1 is dynamic compared to Bcl-2, whereas the p4
pocket is less well defined, shallower and less hydrophobic
than Bcl-xL.
[85] In fact most of the early compounds reported
were pan Bcl-2 inhibitors with the first selective Mcl-1 inhibitor
reported in 2010.[69] There is also a lack of in vivo data for the
majority of compounds reported in the literature, although
this has been addressed very recently by A-1210477, where
the authors argue this is the first description of a small mole-
cule with sufficient potency to have a clear on-target cellular
effect.[80]
Despite these challenges, advances have been made and
the outlook is promising for the discovery of Mcl-1 inhibitors.
New methodologies are being employed to target PPIs which
are proving effective and increasing the hit rate of target-
based screening. The computational approach employed by
Liu and Wang decreases screening time significantly.[75] The
fragment-based approach employed by Fesik allows for smaller
fragment libraries to be evaluated which quickly generates in-
formation about effective ways to target the binding grooves
of the PPI.[74] The recent work of Souers provides a positive
outlook, with potent and selective Mcl-1 inhibitors being de-
veloped through the use of selective assays.[78,79] The exploita-
tion of a combination of these techniques may allow for the
highly efficient development of drug candidates. The examples
of Mcl-1 inhibitors described here demonstrate that the “un-
druggable” challenge that PPIs present can be tackled effec-
tively and is likely to lead to a novel inhibitors for the treat-
ment of cancer.
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Small-Molecule and Peptide Inhibitors
of the Pro-Survival Protein Mcl-1
The anti to pro-survival: The Bcl-2
family of proteins undergo a series of
protein–protein interactions that regu-
late apoptosis. The pro-survival mem-
bers of the Bcl-2 family, including Bcl-2
and Mcl-1, are commonly overexpressed
in a number of cancers. The efficient
modulation of Mcl-1 is still not repre-
sented in the clinic, despite its role in
treatment resistance. This review covers
the progress to date in modulating the
activity of Mcl-1, by both stapled pep-
tides and small molecules.
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